Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 4000
Single User License Price INR 284760
Corporate User License Price USD 12000
Corporate User License Price INR 854280
Site License Price USD 8000
Site License Price INR 569520
Request a Quote

Report Title

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018

Quote Request for License Type
License Type Price  
Single User License USD 4000
Site License USD 8000
Enterprise Wide License USD 12000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018


Quote Request for License Type
License Type Price  
Single User License USD 4000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018



Executive Summary

Bioabsorbable Stents (BAS)-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Bioabsorbable Stents (BAS)-Medical Devices Pipeline Assessment, 2018" provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Bioabsorbable Stents (BAS) under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 9

2 Introduction 10

2.1 Bioabsorbable Stents (BAS) Overview 10

3 Products under Development 11

3.1 Bioabsorbable Stents (BAS)-Pipeline Products by Stage of Development 11

3.2 Bioabsorbable Stents (BAS)-Pipeline Products by Territory 12

3.3 Bioabsorbable Stents (BAS)-Pipeline Products by Regulatory Path 13

3.4 Bioabsorbable Stents (BAS)-Pipeline Products by Estimated Approval Date 14

3.5 Bioabsorbable Stents (BAS)-Ongoing Clinical Trials 15

4 Bioabsorbable Stents (BAS)-Pipeline Products under Development by Companies 16

4.1 Bioabsorbable Stents (BAS) Companies-Pipeline Products by Stage of Development 16

4.2 Bioabsorbable Stents (BAS)-Pipeline Products by Stage of Development 18

5 Bioabsorbable Stents (BAS) Companies and Product Overview 20

5.1 480 Biomedical Inc Company Overview 20

5.2 Abbott Vascular Inc Company Overview 21

5.3 Amaranth Medical Inc Company Overview 22

5.4 Arterius Ltd Company Overview 30

5.5 Biosensors International Group Ltd Company Overview 31

5.6 Biosten, LLC Company Overview 32

5.7 Biotronik AG Company Overview 33

5.8 Biotronik SE & Co KG Company Overview 38

5.9 Boston Scientific Corp Company Overview 39

5.10 Cardionovum GmbH Company Overview 43

5.11 Cordis Corp Company Overview 44

5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 45

5.13 Icon Interventional Systems, Inc. Company Overview 46

5.14 Japan Stent Technology Co., Ltd. Company Overview 47

5.15 Kyoto Medical Planning Co Ltd Company Overview 48

5.16 Lepu Medical Technology (Beijing) Co Ltd Company Overview 49

5.17 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 52

5.18 Manli Cardiology Ltd Company Overview 55

5.19 Meril Life Sciences Pvt Ltd Company Overview 56

5.20 Micell Technologies Inc Company Overview 62

5.21 Michigan Technological University Company Overview 67

5.22 MicroPort Scientific Corp Company Overview 68

5.23 Minvasys SAS Company Overview 69

5.24 MIV Therapeutics Inc Company Overview 70

5.25 NanoCoeur, Inc. Company Overview 72

5.26 North Carolina State University Company Overview 73

5.27 Northwestern University Company Overview 74

5.28 OrbusNeich Company Overview 75

5.29 Pediastent LLC Company Overview 77

5.30 QualiMed Innovative Medizinprodukte GmbH Company Overview 78

5.31 REVA Medical Inc Company Overview 79

5.32 S3V Vascular Technologies Company Overview 85

5.33 Shanghai MicroPort Medical Group Co Ltd Company Overview 86

5.34 Tepha Inc Company Overview 89

5.35 University of Alabama at Birmingham Company Overview 90

5.36 University of Florida Company Overview 91

5.37 VasoTech Inc. Company Overview 92

5.38 Xenogenics Corporation Company Overview 93

6 Bioabsorbable Stents (BAS)-Recent Developments 96

6.1 May 24, 2018: Reva Symposium Showcases Clinical Data 96

6.2 May 23, 2018: Fantom's Positive Two-Year Results Show Sustained Safety and Efficacy 96

6.3 May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR-Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist 98

6.4 May 23, 2018: Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium 99

6.5 May 23, 2018: Fantom's Positive Two-Year Results Show Sustained Safety and Efficacy 100

6.6 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 101

6.7 May 16, 2018: Reva Announces First Implant Of The Fantom Bioresorbable Scaffold In Turkey 101

6.8 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow 102

6.9 May 09, 2018: Reva Medical Announces First Quarter 2018 Financial Results 102

6.10 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 104

6.11 Apr 25, 2018: Xianjian Technology Receives the Most Attention from Institutional Investors 106

6.12 Apr 16, 2018: REVA to Present Full Two-Year FANTOM II Data at EuroPCR 106

6.13 Apr 02, 2018: REVA Initiates Commercial Distribution Partnership in Turkey 107

6.14 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 107

6.15 Mar 27, 2018: REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Switzerland 109

6.16 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 110

6.17 Mar 20, 2018: Micell Technologies Announces Expanded Patent Estate 110

6.18 Mar 08, 2018: REVA Medical Reports Fourth Quarter and Full Year 2017 Financial Results 111

6.19 Mar 01, 2018: GTX Launches USD 99.00 Easy Start Plan for GPS SmartSole and Economy Service Plan as low as USD 14.95 113

6.20 Mar 01, 2018: Study finds the best stent for treatment following a heart attack 114

6.21 Feb 26, 2018: Reva Announces CE Mark And First Implant Of The Fantom Encore Bioresorbable Scaffold 115

6.22 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017 116

6.23 Feb 08, 2018: MicroPort Signs Strategic Agreement with Neptunus Biotechnology 117

6.24 Feb 05, 2018: Reva Appoints Stephen Oesterle As Board Of Directors 117

6.25 Feb 01, 2018: REVA Medical: Quarter Ended 31 December 2017 118

6.26 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 119

6.27 Jan 25, 2018: REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy 121

6.28 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers 121

6.29 Jan 09, 2018: Positive Five-Year Data Published for MiStent in EuroIntervention 123

6.30 Jan 09, 2018: MicroPort Selected as "2017 China Innovative Medical Device Company" 124

6.31 Jan 09, 2018: MicroPort Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation 124

6.32 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 125

6.33 Jan 07, 2018: LifeTech Scientific and Ally Bridge Group Form China-Global Medtech Investment and Operating Partnership 125

7 Appendix 150

7.1 Methodology 150

7.2 About GlobalData 153

7.3 Contact Us 153

7.4 Disclaimer 153

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Bioabsorbable Stents (BAS)-Pipeline Products by Stage of Development 12

Figure 2: Bioabsorbable Stents (BAS)-Pipeline Products by Territory 13

Figure 3: Bioabsorbable Stents (BAS)-Pipeline Products by Regulatory Path 14

Figure 4: Bioabsorbable Stents (BAS)-Pipeline Products by Estimated Approval Date 15

Figure 5: Bioabsorbable Stents (BAS)-Ongoing Clinical Trials 16

1.1 List of Tables

Table 1: Bioabsorbable Stents (BAS)-Pipeline Products by Stage of Development 12

Table 2: Bioabsorbable Stents (BAS)-Pipeline Products by Territory 13

Table 3: Bioabsorbable Stents (BAS)-Pipeline Products by Regulatory Path 14

Table 4: Bioabsorbable Stents (BAS)-Pipeline Products by Estimated Approval Date 15

Table 5: Bioabsorbable Stents (BAS)-Ongoing Clinical Trials 16

Table 6: Bioabsorbable Stents (BAS) Companies-Pipeline Products by Stage of Development 17

Table 7: Bioabsorbable Stents (BAS)-Pipeline Products by Stage of Development 19

Table 8: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Table 9: Absorbable Scaffold Stent-Neonatal Aortic Coarctation-Product Status 21

Table 10: Absorbable Scaffold Stent-Neonatal Aortic Coarctation-Product Description 21

Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 22

Table 12: Second Generation Bioresorbable Vascular Scaffold-Product Status 22

Table 13: Second Generation Bioresorbable Vascular Scaffold-Product Description 22

Table 14: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 15: 80-micron MAGNITUDE Bioresorbable Scaffold-Product Status 23

Table 16: 80-micron MAGNITUDE Bioresorbable Scaffold-Product Description 23

Table 17: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold-Product Status 24

Table 18: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold-Product Description 24

Table 19: FORTITUDE Scaffold-Product Status 24

Table 20: FORTITUDE Scaffold-Product Description 25

Table 21: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold-Product Status 25

Table 22: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold-Product Description 25

Table 23: Second Generation FORTITUDE Scaffold-Product Status 26

Table 24: Second Generation FORTITUDE Scaffold-Product Description 26

Table 25: Amaranth Medical Inc-Ongoing Clinical Trials Overview 27

Table 26: FORTITUDE Scaffold-Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 28

Table 27: FORTITUDE Scaffold-Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds-European Trial 28

Table 28: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold-Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds-Extended Trial II 29

Table 29: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold-Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds-Extended Trial III 30

Table 30: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

Table 31: Arteriosorb Absorbable Drug-Eluting Scaffold-Product Status 31

Table 32: Arteriosorb Absorbable Drug-Eluting Scaffold-Product Description 31

Table 33: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 32

Table 34: Sparrow Drug Eluting Stent System-Product Status 32

Table 35: Sparrow Drug Eluting Stent System-Product Description 32

Table 36: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Table 37: Biodegradable Endovascular Implant-Product Status 33

Table 38: Biodegradable Endovascular Implant-Product Description 33

Table 39: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 34

Table 40: Magmaris Bioresorbable Magnesium Scaffold-Product Status 34

Table 41: Magmaris Bioresorbable Magnesium Scaffold-Product Description 34

Table 42: Biotronik AG-Ongoing Clinical Trials Overview 35

Table 43: Magmaris Bioresorbable Magnesium Scaffold-A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II 36

Table 44: Magmaris Bioresorbable Magnesium Scaffold-BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II 36

Table 45: Magmaris Bioresorbable Magnesium Scaffold-BIOTRONIKS-Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III 36

Table 46: Magmaris Bioresorbable Magnesium Scaffold-Biotroniks-Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV 37

Table 47: Magmaris Bioresorbable Magnesium Scaffold-Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI) 37

Table 48: Magmaris Bioresorbable Magnesium Scaffold-Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction 37

Table 49: Magmaris Bioresorbable Magnesium Scaffold-Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris 38

Table 50: Magmaris Bioresorbable Magnesium Scaffold-Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice 38

Table 51: Magmaris Bioresorbable Magnesium Scaffold-Scaffold Implantation in Emilia-Romagna 38

Table 52: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 39

Table 53: AMS-2-Product Status 39

Table 54: AMS-2-Product Description 39

Table 55: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 40

Table 56: Fully Resorbable Drug-Eluting Scaffold System-Product Status 40

Table 57: Fully Resorbable Drug-Eluting Scaffold System-Product Description 40

Table 58: Next Generation SYNERGY-Product Status 41

Table 59: Next Generation SYNERGY-Product Description 41

Table 60: Boston Scientific Corp-Ongoing Clinical Trials Overview 42

Table 61: Fully Resorbable Drug-Eluting Scaffold System-Fully Absorbable Scaffold Feasibility Study 43

Table 62: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 44

Table 63: CARDIOSORB-Product Status 44

Table 64: CARDIOSORB-Product Description 44

Table 65: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 45

Table 66: SymBio Pimecrolimus/Paclitaxel-eluting Stent-Product Status 45

Table 67: SymBio Pimecrolimus/Paclitaxel-eluting Stent-Product Description 45

Table 68: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 46

Table 69: Xinsorb BRS-Product Status 46

Table 70: Xinsorb BRS-Product Description 46

Table 71: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

Table 72: Biosorb Pediatric Dissolving Stent-Product Status 47

Table 73: Biosorb Pediatric Dissolving Stent-Product Description 47

Table 74: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48

Table 75: Bioabsorbable Stent-Product Status 48

Table 76: Bioabsorbable Stent-Product Description 48

Table 77: Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 49

Table 78: Igaki-Tamai Coronary Stent-Product Status 49

Table 79: Igaki-Tamai Coronary Stent-Product Description 49

Table 80: Lepu Medical Technology (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 50

Table 81: NeoVas Bioresorbable Coronary Scaffold (BCS)-Product Status 50

Table 82: NeoVas Bioresorbable Coronary Scaffold (BCS)-Product Description 50

Table 83: Lepu Medical Technology (Beijing) Co Ltd-Ongoing Clinical Trials Overview 51

Table 84: NeoVas Bioresorbable Coronary Scaffold (BCS)-Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study 52

Table 85: NeoVas Bioresorbable Coronary Scaffold (BCS)-Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial 52

Table 86: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

Table 87: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System-Product Status 53

Table 88: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System-Product Description 53

Table 89: Lifetech Scientific (Shenzhen) Co Ltd-Ongoing Clinical Trials Overview 54

Table 90: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System-A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS) 55

Table 91: Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

Table 92: MIRAGE-Product Status 56

Table 93: MIRAGE-Product Description 56

Table 94: Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 57

Table 95: BioMime-Product Status 57

Table 96: BioMime-Product Description 57

Table 97: BIOMIME AURA-Product Status 58

Table 98: BIOMIME AURA-Product Description 58

Table 99: Meril Life Sciences Pvt Ltd-Ongoing Clinical Trials Overview 59

Table 100: BioMime-A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch-Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions 60

Table 101: BioMime-A Prospective, Single-arm, Multi-center, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions. 60

Table 102: BioMime-Biomime Biosorbable Polymer Sirolimus-eluting Stent in All-comers Patients Treated with Percutaneous Coronary Interventions: The BELLINI Registry 60

Table 103: BioMime-Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis 61

Table 104: BioMime-Real World Drug-eluting Stent Prospective, Open, Multi-site, Registry in Korea: BioMime Stent, Ultimaster Stent Versus Xience Stent by SMart Angioplastry Research Team: SMARTDESK-MX 61

Table 105: BIOMIME AURA-A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch-Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions 62

Table 106: BIOMIME AURA-Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis 62

Table 107: Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 63

Table 108: Bioresorbable Scaffold (BRS)-Product Status 63

Table 109: Bioresorbable Scaffold (BRS)-Product Description 63

Table 110: MiStent SES-Product Status 64

Table 111: MiStent SES-Product Description 64

Table 112: Micell Technologies Inc-Ongoing Clinical Trials Overview 65

Table 113: MiStent SES-A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients with Coronary Heart Disease 66

Table 114: MiStent SES-MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) 66

Table 115: MiStent SES-Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries 66

Table 116: MiStent SES-Multicenter Randomized Study of the Mistent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries 67

Table 117: Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 68

Table 118: Bioabsorbable Stent-Product Status 68

Table 119: Bioabsorbable Stent-Product Description 68

Table 120: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 69

Table 121: Firefalcon Bioresorbable Device-Product Status 69

Table 122: Firefalcon Bioresorbable Device-Product Description 69

Table 123: Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview 70

Table 124: Nile LM SIR Sirolimus Eluting Intracoronary Stent-Product Status 70

Table 125: Nile LM SIR Sirolimus Eluting Intracoronary Stent-Product Description 70

Table 126: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 71

Table 127: Smart-1 DES-Product Status 71

Table 128: Smart-1 DES-Product Description 71

Table 129: Smart-4 DES-Product Status 72

Table 130: Smart-4 DES-Product Description 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

480 Biomedical Inc

Abbott Vascular Inc

Amaranth Medical Inc

Arterius Ltd

Biosensors International Group Ltd

Biosten, LLC

Biotronik AG

Biotronik SE & Co KG

Boston Scientific Corp

Cardionovum GmbH

Cordis Corp

HangZhou HuaAn Biotechnology Co., Ltd.

Icon Interventional Systems, Inc.

Japan Stent Technology Co., Ltd.

Kyoto Medical Planning Co Ltd

Lepu Medical Technology (Beijing) Co Ltd

Lifetech Scientific (Shenzhen) Co Ltd

Manli Cardiology Ltd

Meril Life Sciences Pvt Ltd

Micell Technologies Inc

Michigan Technological University

MicroPort Scientific Corp

Minvasys SAS

MIV Therapeutics Inc

NanoCoeur, Inc.

North Carolina State University

Northwestern University

OrbusNeich

Pediastent LLC

QualiMed Innovative Medizinprodukte GmbH

REVA Medical Inc

S3V Vascular Technologies

Shanghai MicroPort Medical Group Co Ltd

Tepha Inc

University of Alabama at Birmingham

University of Florida

VasoTech Inc.

Xenogenics Corporation

480 Biomedical Inc, Absorbable Scaffold Stent - Neonatal Aortic Coarctation; Abbott Vascular Inc, Second Generation Bioresorbable Vascular Scaffold; Amaranth Medical Inc, 80-micron MAGNITUDE Bioresorbable Scaffold; Amaranth Medical Inc, APTITUDE Sirolimus-Eluting Bioresorbable Scaffold; Amaranth Medical Inc, FORTITUDE Scaffold; Amaranth Medical Inc, MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold; Amaranth Medical Inc, Second Generation FORTITUDE Scaffold; Arterius Ltd, Arteriosorb Absorbable Drug-Eluting Scaffold; Biosensors International Group Ltd, Sparrow Drug Eluting Stent System; Biosten, LLC, Biodegradable Endovascular Implant; Biotronik AG, Magmaris Bioresorbable Magnesium Scaffold; Biotronik SE &; Co KG, AMS-2; Boston Scientific Corp, Fully Resorbable Drug-Eluting Scaffold System; Boston Scientific Corp, Next Generation SYNERGY; Cardionovum GmbH, CARDIOSORB; Cordis Corp, SymBio Pimecrolimus/Paclitaxel-eluting Stent; HangZhou HuaAn Biotechnology Co., Ltd., Xinsorb BRS; Icon Interventional Systems, Inc., Biosorb Pediatric Dissolving Stent; Japan Stent Technology Co., Ltd., Bioabsorbable Stent; Kyoto Medical Planning Co Ltd, Igaki-Tamai Coronary Stent; Lepu Medical Technology (Beijing) Co Ltd, NeoVas Bioresorbable Coronary Scaffold (BCS); Lifetech Scientific (Shenzhen) Co Ltd, Iron-based Drug-eluting Bioresorbable Coronary Scaffold System; Manli Cardiology Ltd, MIRAGE; Meril Life Sciences Pvt Ltd, BioMime; Meril Life Sciences Pvt Ltd, BIOMIME AURA; Micell Technologies Inc, Bioresorbable Scaffold (BRS); Micell Technologies Inc, MiStent SES; Michigan Technological University, Bioabsorbable Stent; MicroPort Scientific Corp, Firefalcon Bioresorbable Device; Minvasys SAS, Nile LM SIR Sirolimus Eluting Intracoronary Stent; MIV Therapeutics Inc, Smart-1 DES; MIV Therapeutics Inc, Smart-4 DES; NanoCoeur, Inc., Nanocoating Cardiac Stent; North Carolina State University, Biodegradable Metal Stent; Northwestern University, Liquid Cast Drug-Eluting Biodegradable Stent; OrbusNeich, Cura Stent; OrbusNeich, Sirolimus-Eluting Absorbable Vascular Scaffold; Pediastent LLC, Pediatric Bioresorbable Stent; QualiMed Innovative Medizinprodukte GmbH, Biodegradable Coronary Stent; REVA Medical Inc, Fantom Encore - 3.0 mm; REVA Medical Inc, Fantom Encore - 3.5 mm; REVA Medical Inc, Fantom Encore - Broader Matrix; REVA Medical Inc, Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold; REVA Medical Inc, Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Thinner Version; S3V Vascular Technologies, 3V Avatar; Shanghai MicroPort Medical Group Co Ltd, Firesorb; Tepha Inc, TephaFLEX Absorbable Coronary Stent; University of Alabama at Birmingham, Endothelium Nanomatrix Coated Stent; University of Florida, Nanocomposite Drug Eluting Stent; VasoTech Inc., PowerStent Absorb DES; Xenogenics Corporation, Ideal BioStent - First Generation; Xenogenics Corporation, Ideal BioStent - Second Generation; Xenogenics Corporation, Whisper Coronary Stent System


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person